Terms: = Liver cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Treatment
154 results:
1. CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.
Cheng K; Zhou Z; Chen Q; Chen Z; Cai Y; Cai H; Wu S; Gao P; Cai Y; Zhou J; Wang X; Wu Z; Peng B
Sci Rep; 2024 Apr; 14(1):8389. PubMed ID: 38600093
[TBL] [Abstract] [Full Text] [Related]
2. Interplay of oxidative stress, cellular communication and signaling pathways in cancer.
Iqbal MJ; Kabeer A; Abbas Z; Siddiqui HA; Calina D; Sharifi-Rad J; Cho WC
Cell Commun Signal; 2024 Jan; 22(1):7. PubMed ID: 38167159
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive Analysis of METTLs (METTL1/13/18/21A/23/25/2A/2B/5/6/9) and Associated mRNA Risk Signature in Hepatocellular Carcinoma.
Wang H; Hu S; Nie J; Qin X; Zhang X; Wang Q; Li JZ
Anal Cell Pathol (Amst); 2023; 2023():6007431. PubMed ID: 38130905
[TBL] [Abstract] [Full Text] [Related]
4. Multi-cohort validation study of a four-gene signature for risk stratification and treatment response prediction in hepatocellular carcinoma.
Liu C; Xiao Z; Wu S; Yang Z; Ji G; Duan J; Zhou T; Cao J; Liu X; Xu F
Comput Biol Med; 2023 Dec; 167():107694. PubMed ID: 37956625
[TBL] [Abstract] [Full Text] [Related]
5. Integrative analysis of multi-omics data reveals inhibition of rb1 signaling promotes apatinib resistance of hepatocellular carcinoma.
He K; An S; Liu F; Chen Y; Xiang G; Wang H
Int J Biol Sci; 2023; 19(14):4511-4524. PubMed ID: 37781033
[TBL] [Abstract] [Full Text] [Related]
6. Network Pharmacology-Based Identification of Key Pharmacological Mechanism of Shen-qi-di-huang Decoction Acting on Uremia.
Zhang X; Chen XF; Chen WJ; Ding H; Zhang BX
Altern Ther Health Med; 2024 Jan; 30(1):44-50. PubMed ID: 37773677
[TBL] [Abstract] [Full Text] [Related]
7. NET G3 vs NEC: p53 and rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
[TBL] [Abstract] [Full Text] [Related]
8. Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes.
Chavda V; Zajac KK; Gunn JL; Balar P; Khadela A; Vaghela D; Soni S; Ashby CR; Tiwari AK
Cancer Rep (Hoboken); 2023 Sep; 6 Suppl 1(Suppl 1):e1821. PubMed ID: 37344125
[TBL] [Abstract] [Full Text] [Related]
9. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast cancer: A Retrospective Real-World Biomarker Analysis.
Gerratana L; Davis AA; Velimirovic M; Reduzzi C; Clifton K; Bucheit L; Hensing WL; Shah AN; Pivetta T; Dai CS; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Ma CX; Puglisi F; Bardia A; Cristofanilli M
JCO Precis Oncol; 2023 May; 7():e2200531. PubMed ID: 37141549
[TBL] [Abstract] [Full Text] [Related]
10. The efficacy and adverse effects of nivolumab and lenvatinib in the treatment of advanced hepatocellular carcinoma.
Wen S; Zeng J; Zhong L; Ye J; Lai X
Cell Mol Biol (Noisy-le-grand); 2022 Nov; 68(11):53-57. PubMed ID: 37114307
[TBL] [Abstract] [Full Text] [Related]
11. Therapeutic application of natural products: NAD
Guo C; Huang Q; Wang Y; Yao Y; Li J; Chen J; Wu M; Zhang Z; E M; Qi H; Ji P; Liu Q; Zhao D; Su H; Qi W; Li X
Phytomedicine; 2023 Jun; 114():154768. PubMed ID: 36948143
[TBL] [Abstract] [Full Text] [Related]
12. Construction and systematic evaluation of a machine learning-based cuproptosis-related lncRNA score signature to predict the response to immunotherapy in hepatocellular carcinoma.
Lu D; Liao J; Cheng H; Ma Q; Wu F; Xie F; He Y
Front Immunol; 2023; 14():1097075. PubMed ID: 36761763
[TBL] [Abstract] [Full Text] [Related]
13. Uterine Leiomyosarcoma Masquerading as a Malignant Perivascular Epithelioid Cell Tumor: A Diagnostic Challenge.
Natsume T; Yoshida H; Nishikawa T; Kikkawa N; Naka T; Kobayashi-Kato M; Tanase Y; Uno M; Ishikawa M; Kato T
Int J Surg Pathol; 2023 Aug; 31(5):778-784. PubMed ID: 36310451
[TBL] [Abstract] [Full Text] [Related]
14. Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumors.
Chen W; Zhang W; Chen M; Yang C; Fang T; Wang H; Reid LM; He Z
Cell Oncol (Dordr); 2022 Dec; 45(6):1053-1071. PubMed ID: 36087253
[TBL] [Abstract] [Full Text] [Related]
15. treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATE.
Raj N; Coffman K; Le T; Do RKG; Rafailov J; Choi Y; Chou JF; Capanu M; Dunphy M; Fox JJ; Grewal RK; Reddy RP; Riedl C; Schoder H; Bodei L; Reidy-Lagunes D
Neuroendocrinology; 2022; 112(12):1177-1186. PubMed ID: 35609558
[TBL] [Abstract] [Full Text] [Related]
16. Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review.
Masuda T; Kosaka T; Nakamura K; Hongo H; Yuge K; Nishihara H; Oya M
BMC Med Genomics; 2022 May; 15(1):118. PubMed ID: 35598018
[TBL] [Abstract] [Full Text] [Related]
17. ZFPM2-AS1: An Oncogenic Long Non-coding RNA in Multiple cancer Types.
Tan F
Mini Rev Med Chem; 2023; 23(1):88-98. PubMed ID: 35578882
[TBL] [Abstract] [Full Text] [Related]
18. NEK2 promotes the progression of liver cancer by resisting the cellular senescence.
Lei Q; Xia J; Feng X; Guo J; Li G; Zhou W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):153-164. PubMed ID: 35545405
[TBL] [Abstract] [Full Text] [Related]
19. Combined Neuroendocrine and Squamous Cell Carcinoma of the Sinonasal Tract: A Morphologic and Immunohistochemical Analysis and Review of Literature.
Agarwal S; van Zante A; Granados ML
Head Neck Pathol; 2022 Dec; 16(4):1019-1033. PubMed ID: 35507300
[TBL] [Abstract] [Full Text] [Related]
20. Emodin-8-O-β-D-glucopyranoside, a natural hydroxyanthraquinone glycoside from plant, suppresses cancer cell proliferation via p21-CDKs-Rb axis.
Li Y; Li K; Zhao Y; Li Y; Li D; Shen L; Wang Q; Yang HS; Sun Z
Toxicol Appl Pharmacol; 2022 Mar; 438():115909. PubMed ID: 35134436
[TBL] [Abstract] [Full Text] [Related]
[Next]